CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Stock Information for CervoMed Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CervoMed Inc.

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD(TM) 2025
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD(TM))
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
CervoMed to Present at the 8th International Lewy Body Dementia Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.